Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12898162 | 0.93 | POLB (0.52) | MAPK14POLBMEN1RAB9AKMT2A | |
| SCHEMBL12898198 | 0.87 | MAPK1 (0.47) | POLBMEN1RAB9AKMT2AMAPT | |
| SCHEMBL12898206 | 0.86 | MAPK1 (0.42) | RAB9AMAPTHTR6LMNATP53 | |
| SCHEMBL12898159 | 0.86 | HTR1F (0.46) | MAPK14POLBRAB9AHTR6 | |
| SCHEMBL12898189 | 0.85 | TP53 (0.48) | MEN1RAB9AKMT2AHTR6LMNA | |
| SCHEMBL12898168 | 0.84 | RAB9A (0.46) | MEN1RAB9AKMT2AHTR6LMNA | |
| SCHEMBL12898178 | 0.83 | POLB (0.51) | POLBMEN1RAB9AKMT2AMAPT | |
| SCHEMBL12898169 | 0.82 | LMNA (0.50) | POLBMEN1RAB9AKMT2AMAPT | |
| SCHEMBL12898182 | 0.80 | HTR6 (0.43) | POLBMEN1RAB9AKMT2AHTR6 | |
| SCHEMBL1268088 | 0.80 | MAPK1 (0.46) | POLBMEN1KMT2AHTR6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-02-17 | — | — | US | disclosed |
| US-20110039893-A1 | GSK-3BETA INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | GSK3B, GSK3A, GSKIP | MAPK14 525/4885POLB 1772/4885GSK3B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.